Table 2.

Probabilities that one drug is better than another regarding responders, in a model without dose level, duration of disease or duration of study

Probability that one drug is better than another given alone
	LD	PRA	ROT	SE	RA	CAB	SA
ROP	0.82	0.99	1	1	1	1	0.94
LD	-	0.93	0.94	1	0.99	1	0.90
PRA	-	-	0.58	0.72	0.84	0.98	0.81
ROT	-	-	-	0.63	0.72	0.96	0.79
SE	-	-	-	-	0.61	0.97	0.76
RA	-	-	-	-	-	0.92	0.73
CAB	-	-	-	-	-	-	0.48
Probability that one drug is better than another in combination with levodopa
	PRA + LD	ROP + LD	ROT + LD	CAB + LD	RA + LD	EN + LD	SA + LD
SE + LD	0.76	0.81	0.92	0.93	1	1	1
PRA + LD	-	0.64	0.94	0.89	1	1	1
ROP + LD	-	-	0.83	0.86	1	1	1
ROT + LD	-	-	-	0.78	0.98	0.99	1
CAB + LD	-	-	-	-	0.56	0.76	0.94
RA + LD	-	-	-	-	-	0.87	1
EN + LD	-	-	-	-	-	-	0.94

RA, rasagiline; SA, safinamide; SE, selegiline; CAB, cabergoline; PRA, pramipexole; ROP, ropinirole; ROT, rotigotine; LD, levodopa; EN, entacapone